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ABSTRACT 
Epigenetic silencing of gene expression has become an intensively studied topic 
regarding breast cancer during the last years. Previous investigations have shown 
that hypermethylation in gene promoters is an alternative to mutations cancer-
related  mechanism  for  inactivation  of  tumor  suppressor  gene  function.  The 
present study was designed for evaluation of promoter methylation in p53 and 
ATM tumor suppressor genes in Bulgarian patients with sporadic breast cancer. 
Sodium bisulfite conversion and methylation-specific PCR were performed on 
tumor  DNA  isolated  from  55  patients  with  sporadic  breast  cancer.  The  data 
showed normal profile of methylation in the promoter region of p53 and ATM 
genes in all studied patients. Cases with hypermethylation were not observed. 
Our  results  did  not  support  the  involvement  of  p53  and  ATM  promoter 
hypermethylation in the neoplastic pathways of sporadic breast cancer. The lack 
of promoter hypermethylation in p53 and ATM is suggestive of a greater share of 
genetic  aberrations  in  loss  of  tumor  suppressor  function  of  these  genes  and 
presumes  the  involvement  of  other  epigenetic  cancer  mechanisms.  To  our 
knowledge this study provides the first data on promoter hypermethylation status 
of p53 and ATM genes in Bulgarian patients. 
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Introduction 
Breast cancer (BC) is a major cause of cancer death in 
women  worldwide.  Recently  established  data  showed 
1384155  newly  diagnosed  BC  cases  globally  a  year, 
estimating  to  22.9%  of  all  cancers  in  women 
(http://globocan.iarc.fr).  In  Bulgaria,  the  newly  diagnosed 
cases are 3655, amounting to 25.8% (Dimitrova et al., 2012).  
The  disease  has  a  complex  multifactorial  nature. 
Carcinogenesis is a multi-step process due to genetic and/or 
epigenetic disorders in a number of tumor suppressor genes 
and proto-oncogenes. Such genes are involved in the normal 
processes  of  cell  growth  and  division,  DNA  repair, 
chromosome segregation, control of cell cycle and cellular 
responses. 
Recent accumulated data support the fact that different in 
nature  epigenetic  processes  can  act  as  an  alternative  to 
mutations  in  the  process  of  carcinogenesis.  Several 
mechanisms  for  epigenetic  alterations  in  cancer  are 
recognized, such as DNA methylation, histone modifications, 
alterations in chromatin condensation, RNA interference. The 
epigenetic  changes  disrupt  gene  function  without  changing 
DNA sequence and can be inherited. Aberrant methylation of 
CpG islands in the promoter area of genes is one of the most 
common epigenetic alterations in human cancers. The CpG 
islands often carry a modified 5-methyl-cytosine, which can 
be maintained in the genome through DNA replication.  
DNA  methylation/demethylation  is  associated  with 
decreasing/increasing of transcriptional activity of genes. The 
maintenance  of  normal  methylation  profile  is  crucial  for ISSN: 1314-6246  Krasteva et al.  J. BioSci. Biotech. 2014, 3(2): 105-109. 
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genomic integrity. Aberrations in methylation pattern lead to 
changes in gene expression and could be a cause for cancer 
development. Unique profiles of promoter hypermethylation 
exist for different tumor types (Esteller et al., 2001). Some 
genes are hypermethylated in various tumor types (p16INK4a 
and MGMT), whereas others - predominantly in specific type 
of tumor (p14ARF and APC in colorectal adenomas, BRCA1 
in  breast  and  ovarian  carcinomas).  In  addition  to  BRCA1 
(13%), hypermethylation in other genes was found in breast 
tumors  (CDH1  -  42%,  GSTP1  -31%,  TIMP3  -  27%, 
p16INK4a - 17%). 
The human p53 is a key tumor suppressor.  It acts as a 
transcription factor, which takes a major part in maintenance 
of  genomic  stability,  differentiation  and  development.  In 
contrast  to  p53  mutations,  which  have  been  elaborately 
studied during the last few decades as a major cancer-related 
mechanism (IARC TP53 data base), the available data on the 
methylation  status  of  p53  are  very  limited.  Recent 
publications reported aberrant methylation in p53 promoter in 
epithelial ovarian cancer (Chmelarova et al., 2013), cervical 
cancer (Jha et al., 2012), oral cancer (Yeh et al., 2003).  
ATM  gene  codes  for  a  nuclear  kinase  involved  in  the 
control of cell cycle, cell death, DNA repair in response to 
double-strand  breaks.  The  ATM  kinase  directly 
phosphorylates  different  downstream  cellular  substrates, 
including  p53.  Germline  ATM  mutations  are  the  cause  of 
Ataxia  telangiectasia.  Hypermethylation  in  ATM  promoter 
was found in tumors of the colon (Bai et al., 2004), head and 
neck (Ai et al., 2004), lung (Safar et al., 2005), lymphoma 
(Huang et al., 2007). 
To our knowledge, the epigenetic status of p53 and ATM 
genes in Bulgarian patients with sporadic BC is not studied. 
In  our  previous  study  we  investigated  the  mutational 
frequency and spectra of  p53 and ATM in a group of 145 
Bulgarian patients with sporadic BC (Bozhanov et al., 2010). 
Here  we  further  explored  the  promoter  hypermethylation 
profile  of  these  genes  in  55  of  the  patients  for  whom 
sufficient  amount  of  tumor  DNA  was  available  using 
methylation-specific PCR assay. Hypermethylation in  ATM 
and p53 promoters was not found. 
Materials and Methods 
Clinical data of patients 
A  group  of  55  female  patients  with  sporadic  BC  was 
studied. Patients were treated at the Specialized hospital for 
active treatment in oncology, Sofia between 2000 and 2003. 
Tumor samples of the patients were provided by Prof. Dr. 
Ivan  G.  Gavrilov.  Clinical  data  and  patients’  informed 
consent  for  conducting  the  research  was  provided  by  Dr. 
Maria B. Nacheva. Clinical information was presented in a 
way preventing identification of patients. Blood samples of 
clinically healthy women were used as negative controls in 
each analysis. 
Patients were staged according to the TNM classification 
of Union International Contre le Cancer (UICC) (Table 1). 
The average age was 53.7 years (SD ± 10,2). The tumor size 
of most patients was relatively small (T1 and T2). Regarding 
to the tumor grade, the majority of patients were diagnosed at 
G2. Almost all patients (52/55) had ductal type of BC. HER2 
overexpression  was  present  in  20%  of  the  patients,  p53 
mutations – in 18.2%, ATM mutations – in 5.5%, PIK3CA 
mutations – in 41.8%. 
 
Table 1. Patients’ clinical and molecular characteristics. 
 
Characteristics  Classification  Total patients 
(n = 55) 
Age, years 
Median 
Range 
<50 
>50 
53,7 
35-78 
20 
35 
Tumor size (T) 
T1 
T2 
T3 
T4 
27 
19 
3 
6 
Grade (G) 
G1 
G2 
G3 
2 
40 
13 
Nodal status (N)  Positive 
Negative 
21 
34 
Histological type  Ductal 
Lobular 
52 
3 
Estrogen receptor (ER)  Positive 
Negative 
23 
32 
Progesterone receptor (PR)  Positive 
Negative 
27 
28 
HER2 
Overexpressed 
Normal 
Unknown 
9 
36 
10 
p53  Mutant 
Wild-type 
10 
45 
ATM  Mutant 
Wild-type 
3 
52 
PIK3CA  Mutant 
Wild-type 
23 
32 
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Patients  were  followed  up  for  a  5 -year  period.  Overall 
survival was estimated to 72.73% (40/55). 
DNA isolation 
Genomic  DNA  was  isolated  from  fresh  frozen  breast 
tumor tissues by a standard Proteinase K/Phenol procedure, 
including tissue homogenization in SE lysis buffer (0.01 M 
Tris/HCl  pH  8.3,  0.4  M  NaCl,  0.002  M  Na-EDTA,  0.14 
mg/ml  Proteinase  K,  1%  SDS)  at  37ºC  for  48  h, 
phenol/chloroform/isoamyl alcohol (25:24:1) purification and 
ethanol  precipitation.  DNA  was  dissolved  into  TE  buffer 
(0.01 M Tris-HCl pH 7.4, 0.001 M EDTA pH 8.0). DNA was 
isolated  from  blood  specimens  of  healthy  controls  using  a 
standard procedure. 
DNA  purity  and  concentration  was  determined  using 
BioSpec-nano Spectrophotometer (Shimadzu Biotech). 
Sodium bisulfite conversion 
A total of 2 μg genomic DNA was used for conversion of 
unmethylated  cytosine  to  uracil,  according  to  the 
manufacturers’  instructions  of  EZ  DNA  Methylation  Kit
TM 
(Zymo Research Corporation, USA). 
Methylation-specific PCR (MSP) 
An amount of 150 ng of the converted genomic DNA was 
used as a template in each  MSP reaction. Primers  used  to 
distinguish methylated (M) and unmethylated (U) DNA (Yeh 
et  al.,  2003;  Ai  et  al.,  2004)  are  listed  on  Table  2  and 
amounted to 20 and 15 pmol of each primer per reaction for 
p53 and ATM genes, respectively. 
A  hot-start  Taq-Polymerase  mix  was  used  (QIAGEN) 
containing 10x PCR Buffer, 5x Q-Solution, 25 mM MgCl2. 
PCR reactions were performed in a total volume of 20 μl. 
PCR cycling parameters for p53 were as follows: 33 cycles of 
denaturation  at  94°C  for  1  min  (first  cycle  –  5  min), 
annealing at 63ºC for 1.30 min and elongation at 72°C for 
1.30 min, followed by a final 5 min extension at 72°C. PCR 
cycling parameters for ATM were: 35 cycles of denaturation 
at 95°C for 30 sec (first cycle – 5 min), annealing at 54ºC for 
30 sec and elongation at 72°C for 1 min, followed by a final 5 
min extension at 72°C. PCR assay was performed on Techne 
Cyclogen and Labnet Multi Gene II. 
PCR  products  were  analyzed  on  3%  agarose  gel 
electrophoresis for 1.30 hours in 1xTBE buffer (89 mM Tris 
base, 89 mM Boric acid, 2 mM EDTA-pH 8.0) and 0.5 μg/ml 
ethidium bromide for imaging under UV. 
Results 
Analysis of promoter hypermethylation profile of p53 gene 
The  optimal  MSP  conditions  were  established 
experimentally.  To  avoid  misinterpretation  of  results, 
unmethylated DNA obtained from clinically healthy persons 
was used as a negative control. Totally methylated in vitro 
DNA was used as a positive control in each PCR reaction. 
We  evaluated  the  level  of  methylation  in  the  promoter 
region of p53 in the studied group of patients with BC. The 
results showed normal profile of methylation in the promoter 
region  of  the  gene  in  all  studied  patients.  Cases  with 
hypermethylation  in  p53  were  not  observed.  Only  310  bp 
amplification  products  were  registered  corresponding  to 
unmethylated  p53  promoter  status.  The  positive  control 
produced 285 bp PCR products (Figure 1). 
Analysis of promoter hypermethylation profile of ATM gene 
The methylation status of ATM gene in the studied group 
of  patients  was  assessed  using  experimentally  optimized 
MSP conditions. The methylation profile was identical to that 
in  the  negative  controls,  demonstrating  lack  of  ATM  gene 
promoter hypermethylation. 
 
Table 2. Primer sequences for unmethylated and methylated DNA template 
 
Gene  Unmethylated  Methylated 
p53 
5’-TTTAAAATGTTAGTATTTATGGTATTAGGTTGGT-3’ 
310bp 
5’-ATTTACGGTATTAGGTCGGC-3’ 
285bp 
5’-CATCATAAAAAACACACTCCCAACCCAAACA-3’  5’-ACACGCTCCCAACCCGAACG-3’ 
ATM 
5’-GTTTTGGAGTTTGAGTTGAAGGGT-3’ 
246bp 
5’-GGAGTTCGAGTCGAAGGGC-3’ 
239bp 
5’-AACTACCTACTCCCACTTCCAA-3’  5’-CTACCTACTCCCGCTTCCGA-3’ 
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Figure  1.  MSP  analysis  of  p53  using  3%  agarose  gel 
electrophoresis. U – unmethylated; M – methylated DNA, 50 
bp  molecular  weight  marker,  T  –  tumor  sample;  K(-)  – 
negative control; K(+) – positive control. 
 
 
 
Figure  2.  MSP  analysis  of  ATM  using  3%  agarose  gel 
electrophoresis. U – unmethylated; M – methylated DNA, 50 
bp and 100 bp molecular weight markers, T – tumor sample; 
K(-) – negative control; K(+) – positive control. 
 
Only  PCR  products  with  the  size  of  246  bp, 
corresponding  to  unmethylated  status  of  the  gene,  were 
detected  (Figure  2).  The  positive  control  produced  239  bp 
PCR products. 
Discussion 
Epigenetic processes may act as alternative to mutations 
through aberration of proto-oncogenes and tumor suppressor 
genes  function,  thus  serving  as  a  basis  for  carcinogenic 
development. The epigenetic alterations differ from genetic 
mainly  in  their  higher  frequency,  partial  reversibility  and 
localization in fixed genome regions. They affect the early 
stages of carcinogenic process nominating them as promising 
markers in early diagnostics.  
The tumor suppressor genes p53 and ATM have been a 
subject  of  profound  investigations  in  view  of  the  genetic 
mechanisms, involved in their inactivation in human tumors. 
However, little is known about the epigenetic impact on this 
process.  There  are  a  limited  number  of  studies  on  the 
methylation status of p53 in breast tumors. Kang et al. first 
demonstrated  presence  of  CpG  methylation  in  the  p53 
promoter in BC tissue (Kang et al., 2001). Hypermethylation 
in p53 promoter correlated with decrease in transcriptional 
activity  (Schroeder  &  Mass,  1997).  Our  analysis  of  p53 
promoter methylation status in a group of Bulgarian patients 
with BC did not lead to identification of hypermethylation 
cases. This lack of aberrant methylation is accompanied with 
a relatively high percentage of p53 mutations found in the 
same patients (32/145 i.e. 22.07%, Bozhanov et al., 2010). 
The mutations spectrum was heterogeneous and specific for 
the Bulgarian patients. Patients with p53 mutations had larger 
tumors,  higher  grade  of  malignancy,  and  poorer  overall 
survival.  Our  results  are  in  agreement  to  those  of  other 
authors  who  found  that  p53  hypermethylation  was  not 
significantly  associated  in  breast  tumors  (Barekati  et  al., 
2010; Pal et al., 2010). However, Kang
 et al. (2001) found 
11.5%  (3  of  26  cases)  of  p53  hypermethylation  and 
concluded that methylation in the p53 promoter region is an 
alternative pathway to neoplastic progression irrespective of 
the status of invasion.  
A limited number of publications proposed aberrant ATM 
hypermethylation  as  a  likely  epigenetic  factor  for  its 
inactivation. Currently, data on the ATM methylation status in 
breast tumors are very limited and contradictory. With the 
exception of a single study (Vo et al., 2004), the data for lack 
of aberrant  ATM promoter  methylation in sporadic BC are 
predominating (Soukupova et al., 2008; Dejeux et al., 2010). 
Our  data  also  showed  absence  of  aberrant  ATM  promoter 
hypermethylation,  which  was  accompanied  with  7.6% 
(11/145)  frequency  of  ATM  mutations  found  previously 
(Bozhanov  et  al.,  2010).  ATM  mutational  spectrum  was 
homogenous. Patients with mutated ATM had predominantly 
tumors  with  lower  grade  of  malignancy  and  lobular 
histological type. 
In conclusion, our results did not support the involvement 
of p53 and ATM promoter hypermethylation in the neoplastic 
pathways  of  sporadic  BC.  However,  such  an  involvement 
could  not  be  excluded.  Other  epigenetic  mechanisms  may 
affect the functional activity of p53 and ATM in the process 
of tumorigenesis. With respect to these genes, the impact of 
genetic mechanisms in sporadic breast carcinogenesis seems 
predominating.  
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